Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed and may not be about the study, with revision updated to v3.3.2. The older PubMed description and revision v3.2.0 were removed.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the site-wide notice about government funding delays; no study content or core details (such as eligibility, outcomes, or locations) are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedThe screenshots show only minor formatting/layout adjustments with no changes to core study details such as objectives, eligibility criteria, interventions, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and the addition of an up-to-date operating status notice (including NIH Clinical Center status and links). Deletion of the previous version tag v3.1.0. overall, indicates a maintenance refresh with updated operating status information.SummaryDifference2%

- Check78 days agoChange Detected- Added new page revision tag: v3.1.0. - Removed several cancer-related topic terms (e.g., Neoplasms by Histologic Type, Carcinoma, Carcinoma, Ovarian Epithelial) and an older revision tag v3.0.2, indicating pruning of topics and a version update.SummaryDifference0.5%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.